The Hepatitis B Virus Receptor

Annual Review of Cell and Developmental Biology

Volumn 31, Issue , 2015, Pages 125-147

  Li, Wenhui ^a  

^a NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

Author keywords

Bile acids; Hepatitis B; NTCP; Pathogenesis; Therapeutics; Transporters

Indexed keywords

PROTEIN INHIBITOR; SODIUM BILE ACID COTRANSPORTER; SODIUM BILE ACID COTRANSPORTER INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS FUSION INHIBITOR; VIRUS FUSION PROTEIN; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; CELL SURFACE RECEPTOR; COTRANSPORTER; MEMBRANE PROTEIN; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ARTICLE; DELTA AGENT HEPATITIS; DRUG TARGETING; ENDOCYTOSIS; GENE EDITING; GENE STRUCTURE; GENETIC PARAMETERS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPG2 CELL LINE; HUMAN; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPECIES DIFFERENCE; VERTICAL TRANSMISSION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PATHOGENESIS; VIRUS RESISTANCE; ANIMAL; METABOLISM;

ANIMALS; CARRIER PROTEINS; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMANS; MEMBRANE GLYCOPROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RECEPTORS, CELL SURFACE; SYMPORTERS;

EID: 84947295748     PISSN: 10810706     EISSN: 15308995     Source Type: Book Series    
DOI: 10.1146/annurev-cellbio-100814-125241     Document Type: Article

References (150)

1. Abou-Jaoude G, Sureau C. 2007. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J. Virol. 81:13057-66
2. AnwerMS, Stieger B. 2014. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch. 466:77-89
3. Barrera A, Guerra B, Lee H, Lanford RE. 2004. Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes. J. Virol. 78:5233-43
4. Barrera A, Guerra B, Notvall L, Lanford RE. 2005. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J. Virol. 79:9786-98
5. Beasley RP, Hwang LY, Lin CC, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2:1129-33
6. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, et al. 2013. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57:1394-406
7. Benhenda S,Ducroux A, Riviere L, Sobhian B, Ward MD, et al. 2013. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J. Virol. 87:4360-71
8. Berquist KR, Peterson JM, Murphy BL, Ebert JW, Maynard JE, Purcell RH. 1975. Hepatitis B antigens in serum and liver of chimpanzees acutely infected with hepatitis B virus. Infect. Immun. 12:602-5
9. Bijsmans IT, Bouwmeester RA, Geyer J, Faber KN, van de Graaf SF. 2012. Homo-and hetero-dimeric architecture of the human liver Na+-dependent taurocholate co-transporting protein. Biochem. J. 441:1007-15
10. Blanchet M, Sureau C. 2007. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J. Virol. 81:5841-49
11. Blanchet M, Sureau C, Labonte P. 2014. Use ofFDAapproved therapeutics withhNTCPmetabolic inhibitory properties to impair the HDV lifecycle. Antivir. Res. 106:111-15
12. Block TM, Gish R, Guo H, Mehta A, Cuconati A, et al. 2013. Chronic hepatitis B: What should be the goal for new therapies? Antivir. Res. 98:27-34
13. Boyer JL, Hagenbuch B, AnanthanarayananM, Suchy F, Stieger B,Meier PJ. 1993. Phylogenic and ontogenic expression of hepatocellular bile acid transport. PNAS 90:435-38
14. Bremer CM, BungC,KottN,Hardt M, GlebeD. 2009. Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell. Microbiol. 11:249-60
15. Burns GS, Thompson AJ. 2014. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb. Perspect. Med. 4:a024935
16. Chen CJ, Yang HI, Su J, Jen CL, You SL, et al. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73
17. Chen HL, Chen HL, Liu YJ, Feng CH,Wu CY, et al. 2005. Developmental expression of canalicular transporter genes in human liver. J. Hepatol. 43:472-77
18. Chen PJ, Kalpana G, Goldberg J, MasonW,Werner B, et al. 1986. Structure and replication of the genome of the hepatitis delta virus. PNAS 83:8774-78
19. Chisari FV, Isogawa M, Wieland SF. 2010. Pathogenesis of hepatitis B virus infection. Pathol. Biol. 58:258-66
20. Chouteau P, Le Seyec J, Cannie I, Nassal M, Guguen-Guillouzo C, Gripon P. 2001. A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus. J. Virol. 75:11565-72
21. Craddock AL, LoveMW, Daniel RW,Kirby LC,WaltersHC, et al. 1998. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am. J. Physiol. 274:G157-69
22. Cui X, Guo JT, Hu J. 2015. Hepatitis B virus covalently closed circular DNA formation in immortalized mouse hepatocytes associated with nucleocapsid destabilization. J. Virol. 89:9021-28
23. Curtil C, Enache LS, Radreau P, Dron AG, Scholtes C, et al. 2014. The metabolic sensors FXRα, PGC-1α, and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. 28:1454-63
24. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. 2013. Pleiotropic roles of bile acids inmetabolism. CellMetab. 17:657-69
25. Dickens C, Kew MC, Purcell RH, Kramvis A. 2013. Occult hepatitis B virus infection in chacma baboons, South Africa. Emerg. Infect. Dis. 19:598-605
26. Dong Z, Ekins S, Polli JE. 2014. Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur. J. Pharm. Sci. 66C:1-9
27. Dorobantu C, Macovei A, Lazar C, Dwek RA, Zitzmann N, Branza-Nichita N. 2011. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein. J. Virol. 85:13373-83
28. Doudna JA, Charpentier E. 2014. Genome editing. The new frontier of genome engineering with CRISPRCas9. Science 346:1258096
29. Drexler JF, Geipel A, Konig A, Corman VM, van Riel D, et al. 2013. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. PNAS 110:16151-56
30. Dupinay T, Gheit T, Roques P, Cova L, Chevallier-Queyron P, et al. 2013. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 58:1610-20
31. Engelke M, Mills K, Seitz S, Simon P, Gripon P, et al. 2006. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 43:750-60
32. Everson GT, Polokoff MA. 1986. HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J. Biol. Chem. 261:2197-201
33. Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. 1994. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology 106:664-73
34. Ganem D, Prince AM. 2004. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350:1118-29
35. Geier A,Wagner M,Dietrich CG,Trauner M. 2007. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773:283-308
36. Gerlich WH. 2013. Medical virology of hepatitis B: how it began and where we are now. Virol. J. 10:239
37. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, et al. 2007. Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J. Biol. Chem. 282:19728-41
38. Geyer J, Wilke T, Petzinger E. 2006. The solute carrier family SLC10: More than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn-Schmiedeberg's Arch. Pharmacol. 372:413-31
39. Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, et al. 2015. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antivir. Res. 121:47-58
40. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. 2003. Pre-S1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J. Virol. 77:9511-21
41. GlebeD,Urban S. 2007. Viral and cellular determinants involved in hepadnaviral entry. World J. Gastroenterol. 13:22-38
42. Glebe D, Urban S, Knoop EV, Cag N, Krass P, et al. 2005. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 129:234-45
43. Gripon P, Cannie I, Urban S. 2005. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79:1613-22
44. Gripon P, Diot C, Theze N, Fourel I, Loreal O, et al. 1988. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J. Virol. 62:4136-43
45. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. 1995. Myristoylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213:292-99
46. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, et al. 2002. Infection of a human hepatoma cell line by hepatitis B virus. PNAS 99:15655-60
47. Guidotti LG, Matzke B, Schaller H, Chisari FV. 1995. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69:6158-69
48. Hagenbuch B,Meier PJ. 1994. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J. Clin. Investig. 93:1326-31
49. Hallen S, Mareninova O, Branden M, Sachs G. 2002. Organization of the membrane domain of the human liver sodium/bile acid cotransporter. Biochemistry 41:7253-66
50. Hardikar W, Ananthanarayanan M, Suchy FJ. 1995. Differential ontogenic regulation of basolateral and canalicular bile acid transport proteins in rat liver. J. Biol. Chem. 270:20841-46
51. Harrison SC. 2015. Viral membrane fusion. Virology 479-80:498-507
52. He B, Fan Q, Yang F, Hu T, Qiu W, et al. 2013. Hepatitis virus in long-fingered bats, Myanmar. Emerg. Infect. Dis. 19:638-40
53. He W, Ren B, Mao F, Jing Z, Li Y, et al. 2015. Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide. PLOS Pathog. 11(4):e1004840
54. Heidrich B, Manns MP, Wedemeyer H. 2013. Treatment options for hepatitis delta virus infection. Curr. Infect. Dis. Rep. 15:31-38
55. Hofmann AF, Hagey LR. 2014. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J. Lipid Res. 55:1553-95
56. Hofmann AF, Hagey LR, Krasowski MD. 2010. Bile salts of vertebrates: structural variation and possible evolutionary significance. J. Lipid Res. 51:226-46
57. Hoh A, Heeg M, Ni Y, Schuch A, Binder B, et al. 2015. Hepatitis B virus-infected HepG2hNTCP cells serve as a novel immunological tool to analyze the antiviral efficacy of CD8+ T cells in vitro. J. Virol. 89:7433-38
58. Hsu PD, Lander ES, Zhang F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262-78
59. Hu NJ, Iwata S, Cameron AD, Drew D. 2011. Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Nature 478:408-11
60. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. 2012. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J. Virol. 86:9443-53
61. Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, et al. 2014. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem. Biophys. Res. Commun. 443:808-13
62. Jinjuvadia R, Liangpunsakul S. 2014. Association between metabolic syndrome and its individual components with viral hepatitis B. Am. J. Med. Sci. 347:23-27
63. Joung JK, Sander JD. 2013. TALENs: a widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14:49-55
64. Jung D, HagenbuchB, Fried M, MeierPJ, Kullak-Ublick GA. 2004. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am. J. Physiol. Gastrointest. Liver Physiol. 286:G752-61
65. Kim HY, Cho HK, Choi YH, Lee KS, Cheong J. 2010. Bile acids increase hepatitis B virus gene expression and inhibit interferon-αactivity. FEBS J. 277:2791-802
66. Konig A, Doring B,Mohr C, Geipel A, Geyer J, Glebe D. 2014. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J. Hepatol. 61:867-75
67. Kuhlkamp T, Keitel V, Helmer A, Haussinger D, Kubitz R. 2005. Degradation of the sodium taurocholate cotransporting polypeptide (NTCP) by the ubiquitin-proteasome system. Biol. Chem. 386:1065-74
68. Kullak-Ublick GA, Beuers U, Paumgartner G. 1996. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23:1053-60
69. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, et al. 1997. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113:1295-305
70. Lai MM. 1995. The molecular biology of hepatitis delta virus. Annu. Rev. Biochem. 64:259-86
71. Lanford RE, Chavez D, Brasky KM, Burns RB 3rd, Rico-Hesse R. 1998. Isolation of a hepadnavirus from the woolly monkey, a NewWorld primate. PNAS 95:5757-61
72. Le Duff Y, Blanchet M, Sureau C. 2009. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J. Virol. 83:12443-51
73. Leistner CM, Gruen-Bernhard S, Glebe D. 2008. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell. Microbiol. 10:122-33
74. Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. 1999. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73:2052-57
75. Li H, Zhuang Q, Wang Y, Zhang T, Zhao J, et al. 2014. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell. Mol. Immunol. 11:175-83
76. Li N, Zhang P, Yang C, Zhu Q, Li Z, et al. 2014b. Association of genetic variation of sodium taurocholate cotransporting polypeptide with chronic hepatitis B virus infection. Genet. Test. Mol. Biomark. 18:425-29
77. Liang D, Hagenbuch B, Stieger B, Meier PJ. 1993. Parallel decrease of Na+-taurocholate cotransport and its encoding mRNA in primary cultures of rat hepatocytes. Hepatology 18:1162-66
78. Locarnini S, Littlejohn M, Aziz MN, Yuen L. 2013. Possible origins and evolution of the hepatitis B virus (HBV). Semin. Cancer Biol. 23:561-75
79. Lucifora J, Arzberger S, Durantel D, Belloni L, StrubinM, et al. 2011. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. 55:996-1003
80. Lucifora J, Esser K, Protzer U. 2013. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antivir. Res. 97:195-97
81. Machado MV, Oliveira AG, Cortez-Pinto H. 2011. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 26:1361-67
82. Macovei A, Petrareanu C, Lazar C, Florian P, Branza-NichitaN. 2013. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J. Virol. 87:6415-27
83. Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, et al. 2010. Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J. Virol. 84:243-53
84. Masuda M, Ichikawa Y, Shimono K, Shimizu M, Tanaka Y, et al. 2014. Electrophysiological characterization of human Na+/taurocholate cotransporting polypeptide (hNTCP) heterologously expressed in Xenopus laevis oocytes. Arch. Biochem. Biophys. 562:115-21
85. Meier PJ, Stieger B. 2002. Bile salt transporters. Annu. Rev. Physiol. 64:635-61
86. Miyajima A, Tanaka M, Itoh T. 2014. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. Cell Stem Cell 14:561-74
87. Muhlfeld S, Domanova O, Berlage T, Stross C, Helmer A, et al. 2012. Short-term feedback regulation of bile salt uptake by bile salts in rodent liver. Hepatology 56:2387-97
88. Mukhopadhayay S, Ananthanarayanan M, Stieger B, Meier PJ, Suchy FJ, Anwer MS. 1997. cAMP increases liver Na+-taurocholate cotransport by translocating transporter to plasma membranes. Am. J. Physiol. 273:G842-48
89. Nassal M. 2015. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut doi: 10.1136/gutjnl-2015-309809
90. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, et al. 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070-83
91. Ochiya T, Tsurimoto T, Ueda K, Okubo K, ShiozawaM,Matsubara K. 1989. An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. PNAS 86:1875-79
92. Oehler N, Volz T, Bhadra OD, Kah J, Allweiss L, et al. 2014. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology 60:1483-93
93. Pan W, Song IS, Shin HJ, Kim MH, Choi YL, et al. 2011. Genetic polymorphisms in Na+-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica 41:501-10
94. Pang QF, Wan XB, Xu AY, Wang ZM, Wang GX, et al. 1981. Hepatitis B virus (HBV) infection in the experimental tree shrews. J. Med. Res. 9:11-12
95. Peng L, Zhao Q, Li Q, Li M, Li C, et al. 2014. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology 61:1251-60
96. Petersen J, Dandri M, Mier W, LutgehetmannM, Volz T, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26:335-41
97. Quasdorff M, Protzer U. 2010. Control of hepatitis B virus at the level of transcription. J. Viral Hepat. 17:527-36
98. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, et al. 2008. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49:652-57
99. Ramiere C, Scholtes C, Diaz O, Icard V, Perrin-Cocon L, et al. 2008. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRα. J. Virol. 82:10832-40
100. Raney AK, Eggers CM, Kline EF, Guidotti LG, Pontoglio M, et al. 2001. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 α-null hepatitis B virus transgenic mice. J. Virol. 75:2900-11
101. Reese VC, Moore DD, McLachlan A. 2012. Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo. J. Virol. 86:2760-68
102. Reese VC, Oropeza CE, McLachlan A. 2013. Independent activation of hepatitis B virus biosynthesis by retinoids, peroxisome proliferators, and bile acids. J. Virol. 87:991-97
103. Rippin SJ, HagenbuchB,Meier PJ, Stieger B. 2001. Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33:776-82
104. Rizzetto M. 2015. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb. Perspect. Med. 5(7):a021576
105. Sarkar S, Bananis E, Nath S, Anwer MS,Wolkoff AW,Murray JW. 2006. PKCδis required for microtubulebased motility of vesicles containing the NTCP transporter. Traffic 7:1078-91
106. Sayin SI, Wahlstr om A, Felin J, Jantti S, Marschall HU, et al. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17:225-35
107. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759-68
108. Schulze A, Schieck A, Ni Y, Mier W, Urban S. 2010. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84:1989-2000
109. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. 2015. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet doi: 10.1016/S0140-6736(15)61412-X
110. Seeger C, MasonWS. 2015. Molecular biology of hepatitis B virus infection. Virology 479-80:672-86
111. Sharma S, Ellis EC, Gramignoli R, Dorko K, Tahan V, et al. 2013. Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes. Drug Metab. Dispos. 41:296-304
112. Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, et al. 2014. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. PNAS 111:12193-98
113. Si-Tayeb K, Lemaigre FP,Duncan SA. 2010. Organogenesis and development of the liver. Dev. Cell 18:175-89
114. Simmonds P, Midgley S. 2005. Recombination in the genesis and evolution of hepatitis B virus genotypes. J. Virol. 79:15467-76
115. Simon D, Aden DP, Knowles BB. 1982. Chromosomes of human hepatoma cell lines. Int. J. Cancer 30:27-33
116. Slagle BL, Andrisani OM, Bouchard MJ, Lee CG, Ou JH, Siddiqui A. 2015. Technical standards for hepatitis B virus X protein (HBx) research. Hepatology 61:1416-24
117. Slijepcevic D, Kaufman C, Wichers CG, Gilglioni EH, Lempp FA, et al. 2015. Impaired uptake of conjugated bile acids and Hepatitis B Virus preS1-binding inNa+-taurocholate cotransporting polypeptide knockout mice. Hepatology 65:207-19
118. SommerfeldA,Mayer PG,CantoreM,Haussinger D. 2015. Regulation of plasma membrane localization of the Na+-taurocholate cotransporting polypeptide (NTCP) by hyperosmolarity and tauroursodeoxycholate. J. Biol. Chem. 290:24237-54
119. Stieger B. 2011. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb. Exp. Pharmacol. 2011:205-59
120. Stross C, Helmer A, Weissenberger K, Gorg B, Keitel V, et al. 2010. Protein kinase C induces endocytosis of the sodium taurocholate cotransporting polypeptide. Am. J. Physiol. Gastrointest. Liver Physiol. 299:G320-28
121. Stross C, Kluge S, Weissenberger K,Winands E, Haussinger D, Kubitz R. 2013. A dileucine motif is involved in plasma membrane expression and endocytosis of rat sodium taurocholate cotransporting polypeptide (NTCP). Am. J. Physiol. Gastrointest. Liver Physiol. 305:G722-30
122. Suk-Fong Lok A. 2015. Hepatitis B: 50 years after the discovery of Australia antigen. J. Viral Hepat. doi: 10.1111/jvh.12444
123. Summers J, Smolec JM, Snyder R. 1978. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. PNAS 75:4533-37
124. Sun AQ, Arrese MA, Zeng L, Swaby I, Zhou MM, Suchy FJ. 2001. The rat liver Na+/bile acid cotransporter. Importance of the cytoplasmic tail to function and plasma membrane targeting. J. Biol. Chem. 276:6825-33
125. Sun E, He J, Zhuang X. 2013. Live cell imaging of viral entry. Curr. Opin. Virol. 3:34-43
126. Sureau C, Guerra B, Lanford RE. 1993. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J. Virol. 67:366-72
127. Sureau C, Salisse J. 2013. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A-determinant. Hepatology 57:985-94
128. Tang H, McLachlan A. 2001. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. PNAS 98:1841-46
129. Taylor JM. 2006. Hepatitis delta virus. Virology 344:71-76
130. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370:901-10
131. Teo CG, Locarnini SA. 2010. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir. Ther. 15:445-49
132. Thomas E, Yoneda M, Schiff ER. 2015. Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb. Perspect. Med. 5:a021345
133. Tong S, Li J, Wands JR, Wen YM. 2013. Hepatitis B virus genetic variants: biological properties and clinical implications. Emerg. Microbes Infect. 2:e10
134. Tuttleman JS, Pourcel C, Summers J. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47:451-60
135. Urban S, Bartenschlager R, Kubitz R, Zoulim F. 2014. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:48-64
136. Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, et al. 2015. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 61:260-67
137. Volz T, Allweiss L, Ben MM, Warlich M, Lohse AW, et al. 2013. The entry inhibitorMyrcludex-B efficiently blocks intrahepatic virus spreading in humanizedmice previously infected with hepatitisBvirus. J. Hepatol. 58:861-67
138. Walter E, Keist R, Niederost B, Pult I, Blum HE. 1996. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24:1-5
139. Watashi K, Sluder A, Daito T,Matsunaga S, Ryo A, et al. 2014. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59:1726-37
140. Wedemeyer H, Manns MP. 2010. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat. Rev. Gastroenterol. Hepatol. 7:31-40
141. Weinman SA. 1997. Electrogenicity of Na+-coupled bile acid transporters. Yale J. Biol. Med. 70:331-40
142. YanH, Liu Y, Sui J, LiW. 2015. NTCP opens the door for hepatitis B virus infection. Antivir. Res. 121:24-30
143. Yan H, Peng B, HeW, Zhong G, Qi Y, et al. 2013. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J. Virol. 87:7977-91
144. Yan H, Peng B, Liu Y, Xu G, He W, et al. 2014. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J. Virol. 88:3273-84
145. Yan H, Zhong G, Xu G, He W, Jing Z, et al. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049
146. Yang D, Zuo C, Wang X, Meng X, Xue B, et al. 2014. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. PNAS 111:E1264-73
147. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97-101
148. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, et al. 2015. Towards an HBV cure: state-of-The-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 64:1314-26
149. Zhong G, Yan H, Wang H, He W, Jing Z, et al. 2013. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J. Virol. 87:7176-84
150. Zhou X, Levin EJ, Pan Y, McCoy JG, Sharma R, et al. 2014. Structural basis of the alternating-access mechanism in a bile acid transporter. Nature 505:569-73